Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

July 21, 2022

New York Stock Exchange US Consumer Staples Tobacco earnings 63 min

Earnings Call Speaker Segments

James Bushnell

executive
#1

Good day, and thanks for being with us. We released a press release earlier today that has the full details about our results for the second quarter of 2022. That release is available on pmi.com. A glossary of terms — covering the definition of reduced risk products, or RRPs, along with adjustments, other calculations and reconciliations to the most directly comparable U.S. GAAP measures, plus additional heated tobacco unit market data — can be found at the end of today's webcast slides, which are up on our website. Except where we say otherwise, whenever we refer to IQOS, we mean our IQOS heat-not-burn products, and whenever we refer to smoke-free products, we mean our RRPs. The growth rates we show on an organic basis reflect adjusted results that are currency-neutral, leaving out acquisitions and disposals. As was the case last quarter, figures and comparisons on a pro forma basis completely leave out PMI's operations in Russia and Ukraine. As we said before, beginning in the second quarter of 2022, and on a comparative basis, PMI will leave amortization and impairment of acquired intangibles out of its adjusted results. Remarks today include forward-looking statements and projections of future results. Please turn your attention to the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could make actual results differ materially from projections or forward-looking statements. It's now my pleasure to introduce Emmanuel Babeau, Chief Financial Officer. Over to you, Emmanuel.

Emmanuel Babeau

executive
#2

Thank you, James. Congratulations on stepping into your new position, and hello to all of you. Prior to getting started, I'd like to restate how committed we are to helping our team members and their families impacted by the conflict in Ukraine, and most importantly, to keeping our people safe. We keep rolling out pledged humanitarian aid along with extra benefits for our staff in Ukraine. As we shared earlier, our plan is to leave the Russian market in a methodical way, since the difficulties of staying operational there keep mounting — things like supply chain issues and constraints in the financial and banking sectors. We're still actively exploring ways to accomplish this amid a regulatory and operating landscape that is growing more complicated and shifting quickly, which includes needing to secure specific government approvals for any deal. Now, on to our business: we showed solid underlying momentum during the second quarter of 2022, posting yet another period of positive volume that supported top and bottom line growth above what we had expected. What stood out most was IQOS continuing to perform excellently, along with robust Q2 pro forma user growth exceeding 1.1 million, which shows further sequential acceleration versus Q1 as device limitation and COVID restrictions keep loosening; this mirrors powerful momentum across the EU region, Japan and developing market. Q2 RP pro forma net revenues rose by plus 11% even with the negative shipment timing effect caused by supply chain constraints that we flagged last quarter, while HTU IMS volumes increased by plus 20%. IQOS ILUMA produced even more remarkable results across its first 3 markets of Japan, Switzerland and Spain. The speed-up in category growth within these varied geographies underscores the thrilling future growth potential worldwide, including in the most recent launch market of Greece. On the combustible side, solid Q2 pro forma volume growth of plus 2.4% and organic net revenue growth of plus 4.2% came from Marlboro share gains, stronger pricing and the ongoing recovery of the markets. Holding onto our leadership position in the cigarette category lets us maximize the switching of adult smokers toward smoke-free alternatives and speed up our transformation into a business that is predominantly smoke-free by 2025. We anticipate that the robust underlying momentum our business showed in H1 will carry on, and we are from an organic growth outlook for the year. At this point we're firmly on track to achieve 2 consecutive years of volume growth, affirming our standing as a growth company when it comes to volumes, organic net revenues and margins. Even with a significant currency headwind in 2022, we expect to achieve full year adjusted diluted EPS of approximately $6, including Russia and Ukraine. The proposed addition of Swedish Match would further enhance our future financial profile. This offer creates value for both sets of shareholders, with a strong strategic and cultural fit, giving us one more chance to speed up our smoke-free future. Now for the headline figures. Our Q2 volumes increased by plus 3% on a pro forma basis and by plus 1.1% in total, including Russia and Ukraine. On a pro forma basis, net revenues rose organically by 6.2%, and total PMI was up 5.3%, which mirrors both IQOS continuing its strong expansion and the combustible business still recovering across numerous markets versus a comparison shaped by the pandemic. Just as we had expected and previously signaled, a less unfavorable cigarette shipment timing also contributed, particularly from duty-free inventory replenishment. Our organic net revenue per unit on a pro forma basis increased 3%, and in total it increased 4.1%, even with the anticipated delay of HTU shipments into Japan while we navigate worldwide supply chain disruption. That figure includes combustible pricing up 3.5% on a pro forma basis, or nearly 5% if Indonesia is excluded. For Q2, our adjusted operating income margin fell organically 190 basis points pro forma, and 150 basis points in total. As anticipated and communicated during our Q1 quarterly results, four main factors explain this: first, investment aimed at further expanding our smoke-free portfolio and keeping pace with its growth. This covers the initially higher cost of ILUMA devices and HTUs, plus the temporary dilutive margin effect from greater device sales as we roll out ILUMA and refill the distribution channel as device constraints loosen to support IQOS user growth reaccelerating. Second, supply chain disruption effects, especially from the war in Ukraine, including roughly $80 million of extra air freight expenses. Third, about 4% inflation in our cost of goods, caused by the global pandemic recovery and worsened by the war, particularly for certain direct materials, wages, energy and transportation costs. And finally, a difficult prior year margin comparison that had included substantial cost of goods sold productivity savings. Even with these typical margin pressures, our strong top line growth and continued cost efficiency let us deliver 5.6% growth in pro forma currency-neutral adjusted diluted EPS, above expectations, at $1.32, and 3.8% growth for total PMI, at $1.48, including Russia and Ukraine. Turning to the first half of the year, our volumes rose 4% on a pro forma basis and 2.2% for total PMI. Pro forma revenues increased 8.1%, and 7.1% in total, again powered by strong IQOS results and the cigarette category's recovery; we achieved organic net revenue per unit growth of 4% on a pro forma basis and 4.7% in total, once more reflecting the favorable effect of rising HT volumes and pricing. Our H1 adjusted operating income margin shrank organically 110 basis points pro forma and 90 basis points in total, because of the factors already mentioned. We anticipate stronger margin performance in H2, which I will go over shortly. Currency-neutral adjusted diluted EPS rose 10.4% to $2.79 on a pro forma basis and 9.2% in total to $3.06, an outstanding result under the circumstances. Given that momentum, here's what we're looking at for 2022. Because IQOS is growing strongly and combustible products continue to perform well, we anticipate faster currency-neutral growth than we previously projected. To start, total pro forma shipment volume for 2022 should now rise by 1.5% to 2.5%, which would mark yet another year of volume gains. On pro forma net revenue, we're looking at organic growth of 6% to 8%, up from the 4.5% to 6.5% we announced earlier, even though hyperinflationary accounting in Turkey is creating a bigger drag than we had expected. Device volume is recovering nicely, ILUMA is contributing more (with a higher unit cost at the outset), and inflation continues worldwide, so we're narrowing our forecast for pro forma adjusted organic OI margin expansion to 0 to plus 50 basis points. We're also lifting our outlook for pro forma currency-neutral adjusted diluted EPS growth to 10% to 12%. That works out to a range of $5.23 to $5.34, and it includes an estimated unfavorable currency hit of $0.80 at prevailing rates, largely from the euro and Japanese yen. We'll have a slide in the appendix covering that estimated impact in more detail.

Emmanuel Babeau

executive
#3

If you take our total PMI figure and count on both Russia and Ukraine being in the mix for all twelve months, then adjusted diluted EPS ought to come in somewhere from $5.90 to $6.05. The same forces reflected on a pro forma basis are captured here, and currency working against us is estimated to subtract $0.69. Keep in mind that nothing from the proposed Swedish Match combination is factored into our 2022 forecast. Closing is anticipated during this year's fourth quarter, provided Swedish Match shareholders give their approval and the necessary regulatory clearances come through. IQOS is set for outstanding growth. Our updated projection for pro forma HTU shipments across the whole year is now 90 billion to 92 billion units, placing us in the upper half of the range we had previously guided. The momentum behind our growth is extremely strong, which means the primary constraint preventing us from lifting our HTU volume goal even higher is available production capacity — especially when it comes to ILUMA HTUs, because of how remarkably well they performed at launch and because we ended manufacturing in Russia while we repurpose an existing line to make induction consumables. We continue to anticipate outstanding HTU growth over the coming quarters, along with gradual gains in ILUMA HTU capacity as we move through the first half of 2023. So we're putting our focus on the markets where ILUMA is launching, and as we've said before, there are more launches coming in Q4. One other thing worth flagging about our outlook: we now expect operating cash flow of roughly $10.5 billion, which is up from the roughly $10 billion we'd been forecasting, and that's even with some pretty significant currency headwinds. That number reflects both our faster pro forma earnings growth projection and the assumption that Russia and Ukraine contribute for the full year. In H1, our operating cash flow growth was strong at plus 14%. And as the difficulties of the past few years have shown, this business's ability to generate cash is still outstanding. Although 2021 was somewhat muted due to advantageous timing and a singular event, our updated projection for the entire year shows fundamental expansion when measured against that remarkable prior year, even after factoring in increased working capital demands caused by inflation and foreign exchange effects. This highlights our capacity to uphold a robust financial position, reduce our borrowings, and put money into expanding our operations. As of June 30, 2022, our net debt stood at $23 billion, which is lower than what we reported at both June and December of 2021, even with $0.5 billion in capital expenditure during the first half and continuous dividend distributions. We remain firmly dedicated to our steady dividend growth approach and anticipate the extra cash flow that the planned merger with Swedish Match would generate. Our full-year capex projection remains roughly $1 billion. Now let's turn to how the second half looks on a pro forma basis. We anticipate solid revenue gains, an improvement in organic adjusted OI margin, and faster growth on the bottom line. Looking at Q3, organic top line growth should land in the mid-single-digit range, powered by IQOS, with pro forma HTU shipment volumes of about $22 billion. Cigarette faces a harder comparison, and shipment timing should create a slight drag, yet we still see combustible volume patterns holding up well relative to history. Turkey's shift to hyperinflationary accounting will continue weighing on net revenue growth in both Q3 and Q4. We think some of the cost squeeze we felt in Q2 will ease up during the third quarter. However, that relief will likely be offset almost entirely, since we're putting a lot more money into smoke-free commercial efforts and R&D. The reason is that during Q3 2021 we had a device shortage holding spending back. With that in mind, our projected Q3 pro forma adjusted diluted EPS comes in between $1.23 and $1.28. Built into that figure is roughly $0.24 of negative currency impact, assuming rates stay where they are now. For Q4, we're looking for a strong showing. HTU shipment volume should bounce back thanks to phasing, and the improvement will be most obvious as HT capacity limits loosen. The second-half rebound in our pro forma adjusted OI margin should likewise lean more toward Q4. Now let's return to our results. Looking at the second quarter and the first half together, pro forma HTU in-market sales volume grew a solid 20%, with the EU region standing out as a key driver. As we expected, pro forma IMS growth in Q2 ran well above shipment volume growth, which ties back to the shipment timing shift I brought up earlier. For the quarter, our total pro forma shipment volume was up 3%, and for H1 it was up 4%. Like I mentioned before, that keeps us in a strong position to achieve volume growth overall for a second straight year, measured both on a pro forma basis and for total PMI. IQOS did really well, and heated tobacco units accounted for 12.6% of pro forma shipment volume in H1, and 14% on a total basis, even though we expected the HTU shipment timing to have an effect in Q2. Our sales mix is shifting quickly too, since our goal is to be a smoke-free-majority company by 2025. Smoke-free net revenues represented nearly 30% of our pro forma total, and for total PMI they came in above 30% during the first half. Roughly 5% of the $4.2 billion in pro forma H1 RRP net revenues came from IQOS devices. That figure reflects more units moved at a lower average price compared with a year ago, a shift that stems from our efforts to broaden the device lineup through VEEV and ILUMA ONE, along with price laddering across our blade device range as we get ready to introduce the premium position in ILUMA. IQOS keeps building positive momentum, and that momentum is picking up speed across numerous markets, which makes it a strong engine for both revenue and margin expansion. In H1, pro forma net revenues grew organically by plus 8.1%, while shipments rose plus 4%. Beyond volume, there are two forces lifting our top line. Pricing is the first, and combustible leads the way there. Next, there's the growing share of RRPs in our portfolio, which carry a higher net revenue per unit and kept producing significant gains; as our transformation speeds up, this is becoming an ever more potent force. Now let's examine what drove pro forma adjusted OI margin, which shrank by 110 basis points on an organic basis. Looking at pro forma figures, gross margin declined 280 basis points organically. That mirrors the factors I mentioned before, since we're investing in our smoke-free business while coping with near-term supply chain disruption and cost inflation. A partial offset came from improved pro forma adjusted marketing administration and reserve costs, which rose 160 basis points organically. Growth in RRP gave us favorable operating leverage, and our cost efficiency initiative paid off too. All told, gross savings reached about $420 million. COGS productivity accounted for roughly $170 million of that, while SG&A contributed more than $250 million. At the halfway mark we've already captured over $1.2 billion in savings, so hitting $2 billion for 2021, 2023 remains firmly on track. That gives us room to put money back into top-line growth and absorb inflationary pressure, all while still expanding margins. We continue to step up spending on our commercial programs, our digital engine and R&D to fuel long-term growth, along with various growth opportunities spanning categories and geographies. Looking at our guidance for the entire year, we anticipate that our operating margin path will strengthen during the back half as short-term pressures and a challenging year-over-year comparison ease. Moving on to combustible, that portfolio again produced gains in pro forma volume alongside organic net revenue for the second quarter.

Emmanuel Babeau

executive
#4

On a pro forma basis, our shipment volume rose 2.4%, compared with a pandemic-hit prior period, with notable contributions from Indonesia, Poland, and Turkey. Beyond that, we kept seeing international duty-free outside Asia bounce back as passenger traffic picks up. Combustible pricing on a pro forma basis came in at plus 3.5%, a touch above what we had anticipated. And although we stay cautious about the economic picture, the pricing backdrop has been steadily getting better. For the full year, we anticipate delivering pricing at a comparable level. Our combustible leadership helps us maximize switching into smoke-free products, and the positive segment share in both Q2 and H1 shows how strong our portfolio is; over time, we keep aiming for a stable category share even with the effect of IQOS cannibalization. This year is the 50th anniversary of Marlboro becoming the leading cigarette brand worldwide; as social consumption occasions returned, Marlboro volumes climbed 7% year-over-year in H1, with category share once again above 10% on a pro forma 12-month rolling basis. Naturally, the brand equity we have built in Marlboro over many years is the strength we are now a smoke-free product as we make excellent progress with IQOS as the undisputed global smoke-free leader. The favorable mix of a stable combustible share and IQOS's ongoing growth puts us in position to deliver total market share growth over time. In Q2, we captured plus 40 basis points of pro forma share gain, including gains in duty-free, Italy, Japan, and Turkey. What's more, PMI HTU reinforced its standing as the second largest nicotine brand in markets where IQOS is available, with a 7.5% share, excluding Russia and Ukraine. Turning now to IQOS performance; we estimate roughly 19 million IQOS users as of June 30 on a pro forma basis; that reflects very strong growth of more than plus 1.1 million users in Q2 and plus 2.2 million in H1, a record first half high on this basis. The acceleration in IQOS user growth versus both Q1 and last year came from the reactivation of acquisition and retention programs in many markets as device supply constraints eased, along with the impressive start of IQOS ILUMA. While device supply constraints have eased in recent quarters, that is largely thanks to the success of our own proactive effort. Global semiconductor supply is still tight, and we continue to monitor and manage the situation closely. In the EU region, we are now nearing the milestone of 9 million IQOS users, reflecting stepped-up commercial activities to drive acquisition and retention, along with the launch of ILUMA in Switzerland and Spain. Our second quarter HTU share rose by plus 1.6 points to 7.1% of total cigarette and HTU industry volume. As noted in prior years, sequential share versus Q1 was affected by the usual seasonality of the combustible market, with the additional element of a strong year-over-year combustible recovery this quarter. Most importantly, IMS volume continued to show robust sequential growth, and we expect that to continue in the second half. This robust showing reflects impressive gains in users and volumes throughout the area, with Italy and Poland standing out as key contributors. Let me now add more detail regarding how we're doing in that region. Featured here is a snapshot of several leading cities, including Texas, during Q2. Even with the denominator impact from the combustible segment that I referenced earlier, our share figures are still quite robust. The standout is Vilnius, which became the first city anywhere to exceed a 40% share, while Athens, Budapest, and Rome sit in the middle-to-upper 20% range. In other places, we're particularly happy with how things look in London, Vienna, and Zurich; over in Japan, IQOS ILUMA is fueling momentum and our market share keeps climbing in important cities like Tokyo. Above all, our IMS volume trajectory is holding up well, with sequential gains continuing. As we flagged last quarter, Q2 shipments came in lower because of timing issues and ought to bounce back during the latter half, weighted toward Q4. The adjusted share for our H2 brands rose by 1.9 points, hitting a record 22.9% in Q2, even with seasonal patterns at play. Though these numbers make us quite happy, our share gains might have come even faster. The combustible segment proved notably sturdy this quarter, and our rollout of mainline price entire HTUs meant for use alongside ILUMA ran a bit behind what we'd originally intended. Still, initial outcomes looked promising. < > is built to serve its consumers who are moving to ILUMA as well as more budget-conscious legal-age smokers. We likewise saw more legal-age users making the switch from lower-priced rival heat-not-burn products. We figure that users of competing offerings tend to consume less per day on average because of weaker full conversion, something we think ILUMA will enhance as time goes on. Heat-not-burn now accounts for roughly one-third of all tobacco in Japan, with IQOS powering a growing portion of this year's expansion. Beyond the solid gains in developed nations, we keep witnessing highly encouraging IQOS growth across low and medium income markets. The pro forma share for our HTU brands in the 28 such markets that launched by December 31, 2021, kept expanding, hitting 2.9% in Q2, which mirrors steady IMS volume growth. Considering how big this market is, the premium positioning of the current IQOS lineup, and how early we are in commercialization, this marks exceptional progress. A clear illustration of this is Lebanon, where Q2 offtake share in Beirut climbed by 8.1 points to 17.4%, and Egypt, where offtake share in Cairo hit roughly 5% after launching under 1 year ago. Additional noteworthy wins include the freshly launched markets of Morocco and Tunisia, plus Georgia, Jordan, North Macedonia, and the Philippines, despite pandemic restrictions in Manila. Turning next to IQOS ILUMA, which kept boosting conversion and retention rates throughout its initial launch markets. In Japan, ILUMA maintained robust expansion, with premium priced TEREA HTUs surging quickly to rank as the second biggest tobacco brand, achieving an offtake share of 14.6% within 9 months of its national launch. On a positive note, SENTIA's offtake share has already climbed past where HEETS stands in < > prefectures, which represent roughly 45% of industry volume. With ILUMA ONE added to our device lineup in Q1, we've also witnessed strong uptake among legal-age smokers. We closed Q2 at an all-time peak for tech share, and we still anticipate a lengthy growth trajectory for ILUMA in Japan across the quarters ahead. In Spain and Switzerland, ILUMA and TEREA HTUs keep enjoying their excellent launch as well. We brought ILUMA to Spain in March 2022, and early results have been highly favorable, particularly in major cities like Barcelona and Madrid. Sequential IMS volumes rose 27% during Q2. TEREA finished the quarter accounting for more than 50% of HTU sales, just 4 months after commercialization, while our national HTU share has increased to plus 1.7%. That's particularly heartening given Spain is a market where regulatory restriction had slowed the pace of IQOS growth. Demand for ILUMA in Switzerland stays extremely robust. IMS volume kept rising sequentially, up plus 13% in the second quarter. A substantial share of current users have moved up to ILUMA, and TEREA's offtake exit volume is now above 70% of our HTU sales.

Emmanuel Babeau

executive
#5

Our global smoke-free portfolio keeps growing, driven by a strong innovation pipeline. In Greece, we introduced ILUMA at the end of June, and additional market rollouts are scheduled during Q4. As for the new heat-not-burn product designed for low and middle income markets, pilot launches remain on track for the fourth quarter, which extends our portfolio further so we can meet varied consumer needs and divide the market into segments. Turning to e-vapor, IQOS kept producing encouraging results — it now ranks as the established #2 closed pod brand in Italy, for instance, with offtake share rising sequentially to roughly 20%. This is a premium proposition carrying an average price premium of 20% to 30% versus competing devices, as we aim for a differentiated and profitable leadership position in the category over time. During Q2, we entered 3 more geographies, France among them, bringing our presence to 10 markets. The newest member of our e-vapor lineup is the Viva disposable device — a responsibly marketed disposable e-vapor product that can serve an important role as a convenient, hassle-free way for legal-age smokers to enter the smoke-free category. Viva recently arrived in Canada with 9 varieties. Our geographical expansion of smoke-free products carried on in Q2 as well, with IQOS launching in Bahrain. Naturally, the largest potential near-term addition to our smoke-free portfolio is the proposed combination with Swedish Match, which would greatly accelerate our transformation into a smoke-free company. Both companies share aligned visions of reaching a smoke-free future without cigarettes, and together we would create a global smoke-free champion. Should it be completed, we would hold a comprehensive global smoke-free portfolio with a leadership position in heat-not-burn plus the fastest growing oral nicotine category, along with potential for faster international expansion. A further compelling rationale for this deal is the large, attractive and expanding U.S. smoke-free market. Swedish Match brings the leading nicotine pouch franchise there along with a substantial U.S. operational platform, which would help us unlock significant opportunity across other smoke-free categories in the years ahead. This would be a strong strategic and cultural fit, offering meaningful shareholder value creation over the medium and long term. As set out in the offer document published on June 28, the waiting period under the U.S. antitrust process for the transaction has expired, which means we have satisfied our U.S. requirement to proceed with the transaction. We anticipate the transaction closing in the fourth quarter of this year, subject to acceptance by Swedish Match shareholders and the necessary regulatory approvals. Turning to sustainability. First, I want to direct your attention to our 2021 integrated report, published in May, which lays out our new sustainability strategy and ESG performance in detail as we keep transforming for good. The report also contains our new sustainability index, made up of 19 KPIs spanning our most material sustainability issues. That index is weighted toward product transformation and now accounts for 30% of our long-term performance-based equity executive compensation. Details on how we measure, the approach taken, and what falls within the boundaries of every one of these KPIs appear in the ESG KPI protocol we released not long ago, which gives greater clarity about the way we characterize success along with key sustainability performance. When it comes to confronting climate change, it brings me great pleasure to announce that as of today, the science-based target initiative has given validation to our 2040 net-zero goal. That same organization also renewed its validation of our nearer-term 2030 objective for cutting greenhouse gas emissions, as well as our fresh 2025 aim calling for 15% of our suppliers to have established their very own science-based target by 2025 — a highly encouraging step forward, considering that Scope 3 continues to be the toughest element of any decarbonization plan a company might pursue. To help make good on these commitments, we are speeding up our efforts to remove carbon from our chain, and an additional 8 factories have become carbon neutral during this year, which is more than twice as many as last year and keeps us on schedule to reach our aim of covering every factory by 2025. Last but not least, the health impact of our products stays among our top ESG concerns. Evidence from science and the real world keeps accumulating regarding the considerable potential for risk reduction that smoke-free products offer when set against smoking. We keep backing policy and fiscal frameworks that acknowledge the beneficial effect a tobacco harm reduction approach can deliver for public health. Illustrations from recently include an extra multiyear tax plan in Romania with differentiated treatment for smoke-free products, plus a statement from the Belgian Super Health Council regarding the role e-vapor products overall can play in helping adult smokers move away from cigarettes. Wrapping up today's presentation, we achieved a strong first half in spite of certain difficult headwinds, which leaves us solidly on track to produce robust volume growth along with an accelerated currency-neutral pro forma financial performance during 2022. The encouraging results from IQOS ILUMA continue to excite us. Greater consumer satisfaction is pushing retention and conversion higher, and we anticipate additional market launches before this year ends. Our combustible business keeps delivering solid results through pro forma volume and organic net revenue growth, holding our market share steady across time even with the effect of IQOS cannibalization, which lets us speed up the shift of smokers toward better alternatives and put money into long-term growth through creating innovative wellness and health care products that aim to generate a net positive impact on society. We keep expanding our pipeline of smoke-free innovation, including ILUMA and Viva, to broaden and grow into new and existing categories and geographies. We are increasing our pro forma growth guidance for the entire year and anticipate delivering roughly $6 in total adjusted diluted EPS, Russia and Ukraine included, despite currency headwinds. Crucially, thanks to a superb 2021 performance and our robust 2022 outlook, we now anticipate comfortably surpassing our 2021 to 2023 minimum CAGR target on a pro forma basis of greater than plus 5% in organic net revenue growth and greater than plus 5% in currency-neutral adjusted diluted EPS growth. We still fully intend to make the business majority smoke-free by net revenue in 2025; our confidence in how quickly we are transforming remains high. Last, our dedication to giving cash back to shareholders hasn't wavered at all. Reinvesting into the company and our progressive dividend policy stay at the top of our capital allocation priorities, supported by robust cash flow generation. Thanks, and at this point we would be glad to take your questions.

Pamela Kaufman

analyst
#6

I'd like to understand what's behind the impressive momentum in new IQOS users over the past 2 quarters. Are you approaching things any differently? And geographically, where are these users coming from? What portion comes from ILUMA as opposed to earlier IQOS devices? And on that note, how much new user growth do you figure there'd be without the production capacity constraints?

Emmanuel Babeau

executive
#7

Thank you, Pamela. Clearly we're — and I've made this point — extremely happy with how IQOS has performed, and that shows up in the exceptionally robust user growth, which exceeded 1.1 million during the second quarter. For H1, as we've stated, growth hit a record. The encouraging part is that expansion is happening really everywhere geographically. Naturally, certain countries like Italy, Poland and Japan, given how large they are, naturally add more during the quarter. But the truth is, we're seeing excellent trends geographically. I could name places like Romania, Portugal, Hungary — I mean, all of these are smaller countries, yet growth there is truly striking. So I'd say it reflects the fact that IQOS is meeting clear customer expectations, the fact that consumers recognize every advantage available from making the switch away from combustible cigarettes toward the IQOS product. ILUMA definitely plays a part. Yet as you're aware, we're unfortunately restricted right now in how many geographies offer ILUMA — that's Japan, Switzerland and Spain. Greece is in the process of launching. So in that country, it's certainly supporting the performance. But let me be very clear: the performance is broad-based, as I mentioned, and includes countries where ILUMA hasn't launched yet. So without question, we're getting better at delivering a superb customer experience — including the digital customer, the way we reach smokers, the way we connect with them, the way we open the conversation, the way we lay out IQOS's benefits and the way we keep them supported along the journey from combustible products over to IQOS. So undoubtedly, our commercial engine keeps getting better, and that's contributing. There's likely also the effect of awareness and visibility, which keep rising. In some markets, once you hit a particular market share, IQOS turns visible — you become more visible when you're in bars, at events, at social gatherings, you notice more and more people. That sets off what we term organic growth — people who wish to find out about IQOS on their own. They're eager to learn, with friends describing how it works and why they genuinely like IQOS. Innovation is speeding up too. We've been introducing new devices. We're introducing new kinds of references. So the range of choices keeps widening, which likely makes IQOS even more desirable and appealing. So really, I believe that's the full set of powerful drivers behind IQOS's success. Now, turning to ILUMA and the potential that more ILUMA capacity would unlock — we observe it in the 3 markets where launches have happened. ILUMA solves the last pain point that existed — that were present with the earlier version of IQOS. It certainly delivers a fantastic customer experience. It lifts conversion and loyalty. We anticipate it will also raise average daily consumption and considerably cut <<inaudible>>. We're seeing the customer net promoter score climb in those countries. So obviously that adds momentum in every country where ILUMA launches. And I think we ought to view it as a sort of second stage of the rocket we'll fire in various countries to push IQOS even higher, and that's our expectation across the countries where launches will occur in the quarters ahead.

Pamela Kaufman

analyst
#8

That's quite useful. I'd also like to understand how you'd describe your near-term appetite for more acquisitions, given the Swedish Match transaction. There are other assets up for sale in the U.S. market. Could you consider pursuing additional acquisitions?

Emmanuel Babeau

executive
#9

Yes. Right now, our attention is on Swedish Match. The time line matches what we anticipated initially; we still expect the deal to close in Q4, naturally, assuming Swedish Match shareholders approve. Nothing has changed. That's where our focus is. Does that mean I'm shutting the door on other opportunities down the road that could speed up our path toward becoming a leading and successful smoke-free company? No; yet obviously, Swedish Match is the priority and the focus at present.

Bonnie Herzog

analyst
#10

I'd like to ask about the pro forma adjusted OP margin you reported for Q2. On an organic basis, it went down, and you pointed out that pressure on margins came at least in part from pricier ILUMA devices as well as HTUs. On top of that, you reduced your guidance for full year OP margin. So I'm hoping you can help us understand how long the rollout of ILUMA might keep weighing on margins. Also, given your FY '22 guidance, which points to slower year-over-year EPS growth in the second half, my assumption is that margin pressure is likely a major factor behind that in the second half, though I'd like you to confirm. And looking ahead toward 2023, should that pressure begin to fade? Or will it persist as you continue to push ILUMA?

Emmanuel Babeau

executive
#11

Yes. Thank you, Bonnie, for asking. So, I mean, it's correct that during H1, we faced several headwinds affecting the margin. Of course, inflation is one, and it goes without saying. We mentioned that we're experiencing roughly 4% inflation on what we pay for inputs. So I'd say that's likely below the inflation seen in many countries, yet it's still meaningful. Clearly, we also have costs stemming from supply chain disruption, particularly those arising from the war in Ukraine; there's a dramatic surge in air freight, which is obviously temporary. We won't continue shipping by air over the long term. However, for a certain period, we have to do it, and it's extremely expensive at a moment when freight costs overall — not just air, but across the board — are rising. So clearly we're being affected; that's definitely having an impact. Then there's the initial launch of ILUMA, especially in Japan, where we made a very, very substantial investment, which was truly essential to make on the device. We now have 2 devices available — actually 3 devices, 3 models in Japan — and the high device volume affects the margin level. Beyond that, as we've said from the start, we don't begin the ILUMA launch with optimized cost and weight on the consumable for TEREA and SENTIA. That shows up early with a negative margin effect, which is also something temporary; so we anticipate that over the course of 2023 it should gradually get better. So inflation isn't temporary. As for everything else, many of the headwinds we're facing in H1 are temporary, and a recovery will come later. At this point, I can't do that, and naturally, as visibility improves, we'll introduce it gradually during the upcoming quarter—but that is definitely our expectation. Then, obviously, for the second half, we anticipate margin improvement. To be sure, that would lean heavily toward the fourth quarter, yet the gross margin decline in the third quarter would already be smaller, though greater investment will come as we expand; we're simply keeping pace with growth and allocating the appropriate amount of investment to handle that growth. In Q4, we'll clearly witness stronger improvement thanks to a better mix. Keep in mind, we've also had margin pressure because the volume we ought to have been shipping—which should have been in the P&L to Japan and carries a very attractive margin—isn't in the P&L; so naturally, that's yet another one-off affecting the first half, but we'll receive compensation in the second half; so yes, a tough start to the year. That doesn't mean everything returns to normal in H2. Some headwind will remain; but clearly, the bulk of what we're dealing with is temporary, and over time, there will be margin recovery.

Bonnie Herzog

analyst
#12

All right, that's clear, and yeah, there are certainly many moving pieces, so I found that useful. Now for my follow-up, regarding the Swedish Match deal you've proposed, could you share a bit more detail about the current status? And also, what do you view as possible dangers that this transaction might fall through? What I mean is, when I consider the activist pressure involved, I'd really like to understand how dedicated you are to getting this done. And what kind of room do you have when it comes to your leverage? As far as I know, you don't have a set leverage target, but you've mentioned before that you intend to keep your investment-grade ratings. So I was hoping you could give me an idea of roughly what leverage level would serve as the cutoff to preserve those ratings.

Emmanuel Babeau

executive
#13

Thanks, Bonnie. Regarding Swedish Match, the first thing I can share is that we've already obtained the required U.S. regulatory clearance, so that step is now complete. Beyond that, reviews continue in multiple jurisdictions as expected, and we're reaffirming our expectation of a Q4 close as previously stated, naturally contingent on approval from Swedish Match's shareholders; and on that point, I want to restate our view that this represents a highly attractive proposal for those shareholders. Let me remind everyone that at the time we announced it in May, we put forward a 40% 4 to 0 premium. Markets have been rather turbulent since then, with most declining, and the Swedish Match Board has given this offer its approval, which affirmed their belief that it delivers compelling value for their shareholders. That's everything I can share about Swedish Match. I have nothing further to add.

Chris Growe

analyst
#14

First, I wanted to ask about how shipments are timed during the back half. You mentioned the roughly 2 billion sticks that got pushed into the latter part of the year. As we consider your guidance for IQOS shipments in 3Q compared with what the fourth quarter implies, does that push land mainly in Q4?

Emmanuel Babeau

executive
#15

Yes, Chris, let me try to assist you. For Q3, what we anticipate is that shipments will align far more closely with the underlying growth we witnessed on the IMS during H1, roughly 20%. That is our expectation for shipments, yet we do not anticipate recovering the shipments that were absent in H1. That recovery should come in Q4, and there we still anticipate quite robust momentum for IQOS consumables. Shipments in Q4 will then exceed IMS so that, for the full year, shipments and IMS are broadly in line. That is the phasing we anticipate for the year.

Chris Growe

analyst
#16

All right. One more thing regarding sales of devices. They've been somewhat higher recently since you had greater supply. Will they stay higher, for example, during the first half of '23, while you keep increasing how many devices you have available? And is that the correct schedule for when you will reach, let's say, complete device availability — the first half of '23, given the chip shortage?

Emmanuel Babeau

executive
#17

Chris, I believe there are 2 factors at play. First, keep in mind that we faced a device availability limitation beginning in Q2, with certain consequences during Q3 and H2 of last year; naturally, then, the device figure rises this year because of weak comparables. That is factor one; and I believe it is truly crucial to grasp how vital it is to guarantee that smokers are able to obtain an IQOS device so they can switch. So making a commercial push here matters, in my view; and I think we are handling that effectively. And we observe that our device, compared with perhaps a device offered by rivals, is evidently achieving superior conversion. Beyond that, regarding factor two, it is evident that ILUMA brings about a replacement wave. Thus, in the markets where ILUMA was introduced, we witness existing IQOS blade devices being swapped for IQOS ILUMA quickly. And this replacement wave generates a very powerful one-time speedup in the device figure. Once people are outfitted — once the main consumer is outfitted, that will be finished, yet we must pass through it. And once more, that is exerting a short-term adverse effect on margin.

Vivien Azer

analyst
#18

My first question concerns the EU's proposed removal of menthol options for heat-not-burn goods. Could you give us some detail on your menthol mix in that region? Then second, what's your view on when that proposal might move forward?

Emmanuel Babeau

executive
#19

Look, I don't know that we've shared the menthol component. Naturally, it's a small portion of what we sell. What I can tell you is that we need to recognize this is an application stemming from the TPD in Europe. So it isn't a decision; rather it applies the TPD of 2014, which under certain conditions envisioned a sort of automatic prohibition taking effect. Now it still requires approval from the parliament and from the European Council, which will be before these 2 bodies later on in 2022, and we'll find out what the final ruling is. To be very clear, this already occurred in the combustible side of the business with nearly no impact or quite limited impact. So consumers rearrange their taste preferences and they move to other products, but quite limited impact. And therefore, it isn't clear that this would carry a meaningful impact should it happen in our heat-not-burn business. Beyond that, we think we hold superiority in our tobacco taste relative to competitors, and that reflects the superiority of our technology with IQOS compared with the technology competitors have. So that would mean if we're left with tobacco taste, our product will stack up well against competitors for people who might choose a new product if they must give up on flavor; so we are, of course, waiting to learn how things develop. But as you can hear, I suppose, from what I've said, we have limited concern about that matter.

Vivien Azer

analyst
#20

Sure, and for my second question, I'd like to talk about IQOS in the U.S. Could we go over once more when that product will be brought back to the marketplace?

Emmanuel Babeau

executive
#21

Right, we anticipate being able to launch IQOS during H1 of 2023. At this point, I'm not able to give anything more specific. Our work on the plan needed to make that happen is ongoing. Naturally, once we have greater clarity and a more exact date for the reintroduction, we'll let you know.

Gaurav Jain

analyst
#22

So I have a few things to ask. First, regarding Russia. The guidance you're giving now covers Russia for the entire year, whereas before, only Q1 had Russia in it. So are you still able to ship devices into Russia — IQOS devices — since IQOS shipments to that country are still happening? And on top of that, are you able to move cash out of Russia to fund the dividends that get paid in USD?

Emmanuel Babeau

executive
#23

Thanks, Gaurav. Yes, I can confirm we're still able to ship our device, and it isn't subject to sanctions. Because of that, plenty of areas of the business are facing supply chain disruption, but this particular one, as things stand — and naturally you can never predict how the situation might change — remains unaffected. As for dividend payments, I can't give you an answer, since we haven't attempted to pay one, so I'm unable to respond. What I can say is that so far, we've continued the regular transfers between our subsidiary, covering procurement as well as royalties or intercompany arrangements as usual. That's all I can share with you at this point.

Gaurav Jain

analyst
#24

All right. My next question concerns Canada. Obviously, Canada isn't consolidated by you, yet volume figures are provided. During 1H '22, that market declined 16%, and in Q2 it fell 19%. Retail pricing, as I understand it, sits at 6% to 7%, nothing unusual there. You've also referred to cannibalization by e-cigarettes, and Viva, the disposable device, has been introduced by you in Canada. So what precisely is taking place there? Are e-cigarettes expanding extremely quickly and eating into the market? Might you assist us in grasping this?

Emmanuel Babeau

executive
#25

Yes. That's a market, I'd say, where a basis of comparison might exist along with a one-off element, yet the direction is unmistakably — don't treat minus 60% as a benchmark for that market. Still, the direction is that combustible business declines while smoke-free product, vaping included, rises — though our ambition also involves fast growth for heat-not-burn, developing well as a combustible substitute. In that market, things shift quickly.

Emmanuel Babeau

executive
#26

Alright, thanks a lot for joining us on this call today; it was a pleasure to walk through the strong momentum we're seeing with IQOS and our shift toward operating as a smoke-free business, even with the difficulties that everyone is aware of. We're eager to speak with you again before long. Thanks so much.

James Bushnell

executive
#27

That wraps up today's session. Thanks once more for being with us. Should any additional questions come up, feel free to reach out to the Investor Relations team. Thanks again, and enjoy the rest of your day.

Operator

operator
#28

That brings today's session to a close. We appreciate you joining us. Feel free to log off whenever you like, and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.